Xyzal and Zosyn drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Xyzal (levocetirizine dihydrochloride) and Zosyn (piperacillin sodium; tazobactam sodium). Common drug interactions include hypersensitivity among females and sepsis among males.

The phase IV clinical study analyzes what interactions people have when they take Xyzal and Zosyn. It is created by eHealthMe based on reports of 37 people who take the same drugs from the FDA, and is updated regularly.

What is Xyzal?

Xyzal has active ingredients of levocetirizine dihydrochloride. It is often used in allergies. eHealthMe is studying from 21,479 Xyzal users. Check the latest studies of Xyzal.

What is Zosyn?

Zosyn has active ingredients of piperacillin sodium; tazobactam sodium. It is often used in pneumonia. eHealthMe is studying from 10,236 Zosyn users. Check the latest studies of Zosyn.



On Jul, 13, 2026

37 people who take Xyzal and Zosyn together, and have interactions are studied.

Xyzal and Zosyn drug interactions.

What are the common drug interactions of Xyzal and Zosyn, by gender? *:

female:

  1. Hypersensitivity
  2. Interstitial lung disease
  3. Oxygen saturation decreased
  4. Pain in jaw
  5. Pharyngeal oedema (abnormal accumulation of fluid in the cavities and intercellular spaces of the pharyngeal)
  6. Pneumonia bacterial (pneumonia associated with bacterial infection)
  7. Respiratory distress (difficulty in breathing)
  8. Sputum retention
  9. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  10. Wheezing (a high-pitched whistling sound made while you breath)

male:

  1. Sepsis (a severe blood infection that can lead to organ failure and death)
  2. Electrolyte imbalance
  3. Osteonecrosis (death of bone)
  4. Pelvic abscess
  5. Perirectal abscess
  6. Platelet count decreased
  7. Procedural pain
  8. Pulmonary function test decreased
  9. Pyrexia (fever)
  10. Rectal abscess (pus in rectum)

What are the common drug interactions of Xyzal and Zosyn, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Anal fistula
  2. Blepharitis (chronic inflammation of the eyelid)
  3. Cerebral infarction (less blood supply to brain resulting tissue damage)
  4. Sepsis (a severe blood infection that can lead to organ failure and death)
  5. Abscess (pus)
  6. Appendicitis perforated (perforated appendicitis is a condition in which an inflamed appendix bursts)
  7. Blood sodium decreased
  8. Drug eruption (adverse drug reaction of the skin)
  9. Drug hypersensitivity
  10. Electrolyte imbalance

20-29:

n/a

30-39:

n/a

40-49:

  1. Chronic kidney disease
  2. Renal failure (kidney dysfunction)

50-59:

  1. Abdominal distension
  2. Anaphylactic reaction (serious allergic reaction)
  3. Asthma
  4. Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection)
  5. Catheter site pain
  6. Catheter site swelling
  7. Diarrhoea
  8. Drug hypersensitivity
  9. Dyspnoea (difficult or laboured respiration)
  10. Dyspnoea exertional (breathlessness or shortness of breath)

60+:

  1. Diarrhoea
  2. Cardiac failure
  3. Injection site erythema (redness at injection site)
  4. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  5. Oedema peripheral (superficial swelling)
  6. Oesophageal rupture (break in oesophagus)
  7. Pleural effusion (water on the lungs)
  8. Relapsing fever (bacterial infection characterized by recurring episodes of fever, headache, muscle and joint aches, and nausea)
  9. Spinal compression fracture (fracture due to spinal compression on bone)
  10. Hypokalaemia (low potassium)

What are the existing conditions these people have? *

  1. Insomnia (sleeplessness): 15 people, 40.54%
  2. Febrile Neutropenia (fever with reduced white blood cells): 11 people, 29.73%
  3. Rashes (redness): 10 people, 27.03%
  4. Pneumonia: 10 people, 27.03%
  5. Adult T-Cell Lymphoma/leukaemia (cancer of the immune system's own t-cells): 10 people, 27.03%
  6. Fever: 10 people, 27.03%
  7. Oedema Peripheral (superficial swelling): 8 people, 21.62%
  8. Type 2 Diabetes: 6 people, 16.22%
  9. High Blood Pressure: 6 people, 16.22%
  10. Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 6 people, 16.22%

* Approximation only. Some reports may have incomplete information.

Do you take Xyzal and Zosyn?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Xyzal and Zosyn:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Xyzal:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Zosyn:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Xyzal and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zosyn and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on levocetirizine dihydrochloride and piperacillin sodium; tazobactam sodium (the active ingredients of Xyzal and Zosyn, respectively), and Xyzal and Zosyn (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: